Increasingly, clinicians and commentators have been calling for the establishment of special adjudicatory dispute resolution mechanisms to resolve intractable medical futility disputes. As a leading model to follow, policymakers both around the United States and around the world have been looking to the conflict resolution provisions in the 1999 Texas Advance Directives Act ('TADA'). In this article, I provide a complete and thorough review of the purpose, history, and operation of TADA. I conclude that TADA is a commendable attempt to balance the competing goals of efficiency and fairness in the resolution of these time-sensitive life-and-death conflicts. But TADA is too lopsided. It is far more efficient than it is fair. TADA should be amended to better comport with fundamental notions of procedural due process.
subset of stalemate cases. But the few that have designed and implemented such mechanisms seem to enjoy some measure of success. 4 Accordingly, many clinicians and commentators elsewhere are calling for the establishment of similar special adjudicatory dispute resolution mechanisms. 5 The paradigm adjudicatory dispute resolution mechanism is a court of law. But almost nobody thinks that is an appropriate model for this type of conflict. 6 First, litigation is cumbersome, being both time-consuming and expensive. Thus, it cannot usefully address complex, urgent medical issues. Moreover, because courts are adversarial and open to the public, they are an unwelcome forum in which to resolve sensitive medical treatment disputes worthy of privacy.
In contrast, the dispute resolution mechanism in the Texas Advance Directives Act ('TADA') is tailor designed for medical futility disputes. It has been in operation for over sixteen years. And policymakers both around the United States and around the world have been looking to TADA as a model to follow. 7 Because TADA is so frequently held up as a model to follow, it merits a careful and thorough examination. The purpose of this article is to critically evaluate TADA and answer three questions. 1) How do TADA's dispute resolution provisions work? 2) Should other jurisdictions adopt them? 3) What changes are required to make TADA's dispute resolution provisions sufficiently fair?
I will proceed in seven stages. In Part II, I provide a brief background on medical futility conflicts. I describe their nature and prevalence. I explain how they can usually be prevented and resolved informally. But, as the growing attention on TADA indicates, medical futility disputes cannot always be prevented or resolved informally. In a significant subset of cases the parties can find no common ground. So, there are, and will continue to be, intractable medical futility disputes.
In Part III, I review the need and demand for dispute resolution mechanisms for these remaining stalemate cases. The status quo is for clinicians to cave-in to surrogate demands for LSMT, even when they think that the administration of such interventions is medically and ethically inappropriate, or even cruel. Clinicians are legally risk averse and reluctant to cause a patient's death without consent. But many clinicians are unhappy with this status quo. Both individual clinicians and hospitals are eager to implement adjudicatory mechanisms to resolve these cases. They see TADA as a leading model.
In Part IV, I turn from explaining the context and motivation for TADA to an examination of the statute itself. First, I provide a brief history of TADA. Second, I summarise TADA's dispute resolution provisions. I walk the reader, step-by-step, through the operation of all six stages of the dispute resolution process. Then, in Part V, I turn from the statutory text to examine TADA in operation on the ground. I describe how Texas hospitals have used TADA over the past sixteen years.
Intractable Medical Futility Conflicts
In Part VI, I turn from a descriptive approach to a normative approach. While TADA is extremely controversial, I argue neither for nor against the core idea that healthcare providers may withhold or withdraw LSMT without patient or surrogate consent. In other words, I am not evaluating 'whether' clinicians should be able to stop LSMT without consent. Instead, I am evaluating 'how' the law authorises them to do that.
Specifically, I evaluate how well TADA comports with notions of procedural due process, the 'oldest of our civil rights.' 8 This is not a constitutional analysis but rather a use of constitutional principles to evaluate fundamental fairness. The requirements of procedural due process under the Fifth and Fourteenth Amendments to the US Constitution embody 'tenets of fundamental fairness.' Accordingly, they provide a useful 'template to help measure' the propriety and fairness of TADA's dispute resolution procedures. 9 Finally, in Part VII, I conclude that TADA is not now sufficiently fair. But state legislatures could easily remedy these defects with modest amendments that have already garnered widespread support among relevant stakeholders.
II BACKGROUND: MEDICAL FUTILITY DISPUTES
To appreciate the motivation for, and purpose of, TADA's dispute resolution provisions, it is first necessary to understand the nature of medical futility disputes. Accordingly, in this section I explain: 1) what is a medical futility dispute; 2) that they are common; and 3) that they can often be prevented. Furthermore 4) even when they cannot be prevented, medical futility disputes can almost always be informally resolved. TADA is designed to address the small, yet significant, subset of cases that remain intractable to communication, negotiation, and mediation.
A What Is a Medical Futility Dispute?
A medical futility dispute is one in which the parties disagree over whether a current or proposed medical intervention is beneficial. 1 0 The paradigmatic medical futility dispute is one in which the patient's substitute decision maker (surrogate) requests aggressive treatment interventions for an imminently dying or catastrophically chronically ill patient. However, that patient's health care providers consider such treatment to be medically or ethically inappropriate.
Medical futility disputes can concern any type of medical intervention. But most of the relevant legislative and judicial activity, as well as most of the academic commentary, involve disputes over LSMT. There are three distinctive features of such disputes.
First, disputes over LSMT involve life-and-death stakes. They usually concern patients in a hospital ICU. LSMT utilises mechanical or other artificial means to sustain, restore, or supplant an individual's spontaneous vital function. LSMT procedures include: assisted ventilation, renal ' Edward L Rubin, 'Due Process and the Administrative State' (1984) 
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dialysis, cardiopulmonary resuscitation ('CPR'), antibiotics, chemotherapy, and artificial nutrition and hydration." 1 Typically, withholding or withdrawing LSMT will result in the patient's death.
Second, ICU patients dependent on LSMT almost never have decision making capacity. They lack the 'ability to understand the significant benefits, risks, and alternatives to proposed health care and to make and communicate a health care decision.' 1 2 They cannot direct their own medical treatment. Consequently, medical treatment decisions for ICU patients must be made by a substitute decision maker or surrogate.
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Third, the typical futility dispute is between the attending physician and the surrogate. The clinician says 'stop,' but the surrogate says 'go. ' The clinician thinks that LSMT is no longer medically indicated and that the appropriate treatment plan is for comfort measures only. The surrogate, on the other hand, rejects this proposed treatment plan, and directs the clinician to continue LSMT.
14

B The Move from Definitions to Process
Since the late 1980s, writers and policymakers have articulated four main definitions of 'medical futility.' Two are narrowly circumscribed and defined by objective clinical criteria: 1) physiological futility and 2) medical ineffectiveness. Two other positions also purport to 'appear' neutral and scientific like the first two: 3) quantitative futility and 4) qualitative futility. But they actually include value-laden criteria. Finding consensus on these two definitions proved problematic and elusive. Lawyers, bioethicists, health care providers, and policymakers have had enormous difficulty defining treatment that is 'futile' or 'medically inappropriate.' Years of debate have failed to produce any consensus.
So, by the mid-1990s, many institutions, professional associations, and commentators abandoned a definitional approach. They abandoned delineating clinical indications that would 'define' medical futility. Instead, paraphrasing Justice Potter Stewart's comment on pornography, many concluded that we can only 'know it' when we 'see it.' 1 6 They instead espoused a procedural, process-based approach. 17 A recent policy statement from five leading critical care medical associations reconfirms this procedural approach. give all decision-making authority either to surrogates or to individual clinicians.
Second, the statement maintains that a process-based approach can incorporate multiple perspectives to minimise the risk that the values of any one individual will carry undue weight. Third, it concludes that a process-based approach better fulfills democratic ideals for resolving conflicts involving fundamental interests. Fourth, the policy statement predicts that a processbased approach may allow mutually agreeable solutions to emerge as the conflict-resolution process unfolds over time.
In short, the multi-society policy statement agrees with TADA that a procedural, and not a definitional, approach is appropriate. But the policy statement specifically rejects the particular procedural approach in TADA as insufficiently compatible with fundamental fairness. A core objective of this article is to more fully explain why.
C Medical Futility Disputes Are Common
Conflicts over LSMT in the ICU are common. The frequency of medical futility conflicts is equally high when measured from the perspective of ICU clinicians. Several recent surveys of critical care specialists demonstrate significant levels of conflict over LSMT. For example, a widely-discussed 2014 study from UCLA found that 20 per cent of the medical interventions in five of its ICUs were either futile or probably futile.
Furthermore, not only is the volume of futility disputes already high but it is also likely to rise even further. There are three main reasons for this. First, the number of patients who are the subject of futility disputes will increase with continued growth: 1) in the ageing population, 2) in the burden of chronic illness, and 3) in the technology used to support vital organ function.
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Second, not only is the number of patients growing but also the rate of conflict is increasing. Physicians are increasingly more likely to recommend comfort measures only, instead of continuing aggressive, curative treatment. This is the result of shifts both in training and in reimbursement incentives. 29 Third, at the same time that physicians are increasingly recommending comfort measures only, surrogates are increasingly likely to resist those recommendations. Largely for cultural, religious, and ethnic reasons, a growing proportion of Americans say that doctors should 'do everything possible to keep patients alive.'
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D Many Futility Disputes Can Be Prevented
It is better to prevent futility disputes from arising in the first place than to work at resolving them after they have already arisen. In fact, prevention is not terribly complicated or difficult. Most patients do not even want aggressive treatment at the end of life. 31 Suppose that these patients still had capacity and could make their own treatment decisions. They and their clinicians would generally agree on the appropriate treatment plan. There would be no conflict.
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But the patients who are the subjects of futility disputes almost always lack decision making capacity and cannot make their own treatment decisions. In such circumstances, they are presumed to want LSMT unless they have adequately rebutted that presumption. Unfortunately, most patients have not 'opted out' of pro-life default rules. As a result, they receive treatment that they would not have wanted and that their clinicians do not want to administer.
Fortunately, rapidly expanding initiatives are helping patients to better understand their options and to better document their treatment preferences. In short, most patients do not want continued LSMT when they are chronically critically ill. If these patients had adequately documented their treatment preferences, most futility disputes could be avoided.
E Almost All Futility Disputes Can Be Informally Resolved
While prevention is a first choice approach, it is not always successful. If prevention has failed and conflict arises, informal and internal dispute resolution mechanisms available within the If the treatment team is not getting anywhere with the surrogate, it can invite the intervention of ethics consultants, social workers, chaplains, palliative care clinicians, the ethics committee, external second opinions, and other experts. These other hospital resources are quite effective at achieving consensus. 36 Indeed, only around five per cent of disputes remain intractable.
Clinicians do not want to act contrary to their professional judgment. Nor do they want to act without patient or surrogate consent. In a medical futility dispute, these two objectives come into conflict. But they are not irreconcilable or mutually exclusive. Consistent with both of these objectives, there are three ways to reach consensus in a futility dispute.
First, as discussed above, the clinician might eventually get consent from the surrogate. With intensive communication and mediation, the physician and surrogate might find some common ground.
Second, consensus might be reached by 'replacing' the objecting clinician with a substitute. Sometimes, the treating clinician can find a new health care provider willing to provide the treatment that the surrogate wants.
37 While the current health care provider may be unwilling to administer the surrogate-requested treatment, it is sometimes possible to transfer the patient to another physician or facility that is willing to provide the disputed treatment.
Third, if neither of these solutions is possible, the clinician is often able to replace the current surrogate with a new surrogate who will consent to the recommended treatment plan. This is the mirror image of the second path to consensus. Instead of transferring the patient to a new health care provider who agrees with the surrogate, the clinician replaces the current surrogate with a new surrogate who agrees with the clinician.
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But while an effective mechanism for many disputes, surrogate selection cannot resolve some significant categories of conflict. In many cases it will be difficult for providers to demonstrate that surrogates are being unfaithful to patient instructions or preferences. Since too few individuals engage in adequate advance care planning, applicable instructions and other evidence regarding patient preferences are rarely available. Therefore, it is often impossible to demonstrate surrogate deviation. Other times, the available evidence shows that the surrogate is acting faithfully and making decisions consistent with the patient's instructions, preferences, and values. 39 In short, most futility disputes can be resolved through reaching consensus in one of three ways: 1) clinicians obtain consent from the current surrogate, 2) clinicians obtain consent from a new 34 Downar, above n 22. Unable to obtain the surrogate's consent to the proposed treatment plan, most clinicians 'cave-in' to surrogate demands. Physicians in most US jurisdictions are afraid to refuse surrogate requested treatment that they deem inappropriate or even cruel. 41 In contrast, TADA has proven effective at allowing (or empowering) physicians to avoid providing medical treatment that they judge medically or ethically inappropriate. Accordingly, other jurisdictions have been looking to TADA as a model to follow.
A Clinicians Want Safe Harbor Legal Immunity
Medical facilities across the United States have developed policies for dealing with medical futility. Indeed, among other professional medical organisations, the American Medical Association ('AMA') recommended a process-based approach. The AMA process includes seven steps: four aimed at 'deliberation and resolution,' two aimed at securing alternatives in cases of 'irresolvable differences,' and a final step aimed at closure when all alternatives have been exhausted. But with respect to this final step, the AMA correctly noted that 'the legal ramifications of this course of action are uncertain.' This uncertainty is 'chilling' and deters clinicians from proceeding without surrogate consent. 43 'Immunity... is critical in the view of most, if not all, practicing physicians.' 44 It is unclear how effective medical futility dispute resolution guidelines can be in the face of legal uncertainty. 45 One Texas physician observes:
In my near 10-year experience with consults related to medical futility, many a physician, nurse, and even hospital ethics committee member felt that certain treatments in a given case were futile 40 Furthermore, still others are looking to copy TADA, though in a less open and transparent manner.
The authors and architects of TADA report that they get calls from around the country from lobbyists and advocates. 65 Plans, strategies, and bills are being drafted and devised. 
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TEXAS ADVANCE DIRECTIVES A CT
Now that we have established the reasons for examining TADA, we can turn to an examination of the statute itself. After providing a brief history of the legislation, I walk through all six steps of its dispute resolution process.
A WhatIsTADA?
The focus of this article is on the unique dispute resolution mechanisms in the TADA. But these provisions are just a small part of the TADA. While TADA spans over 15 000 words, the dispute resolution provisions consist of just around 700 words. TADA is a comprehensive healthcare decisions statute comprised of 71 separate statutory sections. The dispute resolution provisions With respect to LSMT, this can happen in two basic ways. First, the surrogate may be requesting LSMT that the physician thinks is inappropriate. Second, the surrogate may be refusing LSMT that the physician thinks should be provided. The former situation (a medical futility dispute) is the far more common situation and the one on which this article focuses.
TADA encourages the 'physician's refusal' to 'be reviewed by an ethics or medical committee.'
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This review process is comprised of six basic steps that proceed in a roughly chronological order:
1) The attending physician refers the dispute to a review committee.
2) The hospital provides the surrogate with notice of committee review.
3) The review committee holds an open meeting.
4) The review committee makes its decision and provides a written explanation.
5) The hospital attempts to transfer the patient to a willing facility.
6) The hospital may stop LSMT.
TADA mandates that hospitals continue to administer disputed LSMT during the first five steps of this review. 8 9 In addition, TADA specifies two situations under which the process can be shortened or extended.
The Attending Physician Refers the Dispute to a Review Committee
In a futility dispute, at some point, the attending physician determines that one or more forms of LSMT are inappropriate. Since the default presumption is that all physiologically effective LSMT will be provided, the physician ordinarily seeks the consent of the patient's surrogate to a proposed plan to withhold or withdraw treatment. The surrogate refuses consent.
While not required by TADA, the attending physician will typically work on obtaining the TADA' s dispute resolution procedures are written such that the attending physician is the only one who can invoke them. 92 They are triggered when the attending physician 'refuses to honor a patient's advance directive or a health care or treatment decision made by or on behalf of a patient.' 93 The attending physician notifies the review committee of her refusal, effectively asking or petitioning it to adjudicate the dispute.
The Hospital Provides the Surrogate with Notice of Committee Review
Once the attending physician refers the case to the review committee, the committee will convene a 'meeting' to consider the case. Presumably to enable the surrogate to attend and meaningfully participate at the committee hearing, the hospital must inform the surrogate of the committee review process at least two days in advance. Specifically, this notice must be provided 'not less than 48 hours before the meeting called to discuss the patient's directive, unless the time period is waived by mutual agreement.'
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At the same time that it provides notice of the review committee meeting, the hospital must also provide the surrogate with two written documents: 1) a statutorily mandated written 'statement' of rights 95 and 2) a state-maintained list of health care providers and referral groups. 96 TADA encourages, but does not require, the hospital to provide a third document, 3) that describes its committee review process.
(a) The Hospital Provides the Surrogate with a Written Statement of Rights
While not in the original 1999 TADA, a 2003 amendment added specific language that hospitals must provide to surrogates. 97 The required written statement basically summarises the surrogate's rights in plain, less legalistic, language.
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In cases in which the attending physician refuses to comply with an advance directive or treatment decision requesting LSMT, the statement shall be in substantially the following form: Furthermore, the listing of a provider or referral group in the registry 'does not obligate the provider or group to accept transfer of or provide services to any particular patient.' 106
(c) The Hospital Provides the Surrogate with a Description of Its Review Process
While TADA requires hospitals to provide the 'statement of rights' and the 'registry list,' it merely suggests and recommends that the hospital provide the surrogate with a third document: 'a written description of the ethics or medical committee review process and any other policies and procedures related to this section adopted by the health care facility.' 10 7 Since TADA provides almost no direction on how a review committee is to operate, the process will vary from hospital to hospital. At this point, at least 48 hours before the review committee hearing, three things have happened. First, the attending physician has refused to honour the treatment decision for continued LSMT. Second, the physician has referred the case to the hospital review committee. Third, the surrogate has been apprised of her rights.
TADA does not authorise physicians to act unilaterally. The attending physician's refusal must be reviewed by an 'ethics or medical committee.' 1 08 But hospitals have significant discretion here. TADA is mostly silent as to the composition or training of the committee that reviews the dispute between the surrogate and clinician. 10 9 The statute provides only that 'the attending physician may not be a member of that committee.'
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With respect to the meeting itself, TADA provides that the surrogate is entitled to attend. 1 But it does not specify any other rules or procedures. TADA is silent on who else the surrogate may bring (eg an attorney, a religious adviser). It is silent on the scope of the surrogate's participation (eg right to ask questions).
While not specified in the statute, the review committee meeting typically proceeds in two stages. It 'begins with a presentation from the attending physician and other members of the health care team.' 1 12 During this presentation, clinicians 'provide reasoning and evidence to support why they believe further curative care would be medically futile.' 1 1 3 Most committees then 'allow the patient and family to present their arguments and evidence.' 1 14
The Review Committee Makes Its Decision and Provides a Written Explanation
After the meeting, the review committee will usually deliberate in private, separate from the treating clinicians and family. Once it reaches a decision, the committee must prepare a 'written explanation of the decision reached during the review process.' 1 1 5 It must provide the surrogate with a copy. This 'written explanation' must also be included in the patient's medical record.
6
The review committee consideration of a medical futility dispute results in one of three main outcomes. First, the committee can agree with the surrogate. Second, it can agree with the referring physician. Third, sometimes the conflict is mooted by the patient's death or by subsequent familyclinician agreement.
First, if the review committee agrees with the surrogate, then the physician must make a reasonable effort to transfer the patient to a physician who is willing to comply with the surrogate. Hospital personnel must assist the physician in arranging the patient's transfer: 1) to another physician, 2) to an alternative care setting within that facility, or 3) to another facility. 117 Second, if the committee agrees with the referring physician (and it usually does), then the dispute resolution process may continue. Published studies indicate that review committees agree with referring physicians in more than 70 per cent of cases.
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Third, sometimes the conflict is mooted, because the patient dies during the review process. Other times, conflict is mooted, because surrogates are persuaded by the fact that the review process affirms the attending physician's decision that LSMT is inappropriate treatment. 1 20 These surrogates are happy that the committee takes the burden of decision making off their shoulders. 121 On the other hand, some surrogates may consent because they experience the TADA process asfait accompli. 1 
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But while some disputes are resolved by or during the review process, others are not. Some surrogates continue to request LSMT that both the attending physician and the ethics or medical committee concluded was inappropriate.
The Hospital Attempts to Transfer the Patient to a Willing Facility
If the review committee agrees with the referring physician and the surrogate does not agree with that decision, then 'the physician shall make a reasonable effort to transfer the patient to a physician who is willing to comply with the directive.' 1 23 In fact, it is unlikely that another physician at the same facility will accept a transfer at this point in the process. So, TADA further provides: 'If the patient is a patient in a health care facility, the facility's personnel shall assist the physician in arranging the patient's transfer: 2) to an alternative care setting within that facility; or 3) to another facility.' 124 The surrogate may concurrently look for a transfer on her own. She can use the 'registry list' of health care providers and referral groups that have volunteered their readiness to consider accepting transfer, or to assist in locating a provider willing to accept transfer. Surrogates may contact providers or referral groups on the list or others of their choice to get help in arranging a 
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transfer. The patient is responsible for any costs incurred. 125 After being served with the review committee's 'written explanation,' the surrogate has at least ten days to accomplish a transfer. But this is a difficult task. Few hospitals are willing to accept the transfer of a patient after another hospital's review committee has already determined that continuing LSMT is inappropriate. 126 But transfer is not impossible.
1 27 For example, the family of Spiro Nikolouzos transferred him from St. Luke's Episcopal Hospital to Avalon Place, a long-term care facility.
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More recently, a June 2011 case at Texas Children's Hospital garnered significant media attention. A fourteen-year-old boy had been diagnosed months earlier with inoperable glioblastoma, a particularly lethal cancer. The boy's parents were able to transfer him, five days into the ten day waiting period, to Atrium Medical Center, a nearby long-term acute-care facility.
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In these cases in which the surrogate is requesting LSMT 'that the attending physician has decided, and the review process has affirmed is inappropriate treatment, the patient shall be given available [LSMT] pending transfer.' 1 30 But the transfer period is not indefinite.
The Hospital May Stop Life-Sustaining Treatment
The patient must continue to be given LSMT until he or she can be transferred to a willing provider. But the waiting period to find a transfer lasts for only 10 days from the time the surrogate was given the committee's 'written explanation' that LSMT is not appropriate. If a willing provider cannot be found within 10 days, then LSMT may be withdrawn.
Neither the physician nor the health care facility are 'obligated to provide [LSMT] after the tenth day after the written decision' is provided to the surrogate. 1 31 The inability to transfer is intended to serve as confirmation of the review committee's decision. The refusal of other facilities to provide the disputed LSMT supposedly indicates or confirms that the review committee was correct. Accordingly, LSMT 'under this section may not be entered in the patient's medical record as medically unnecessary treatment until the ten day waiting period has expired.' 132 
Special Adjustments to Timing
(f). Intractable Medical Futility Conflicts
The previous six steps fully describe the TADA dispute resolution mechanism. But TADA also specifies two situations under which this standard dispute resolution process can be shortened or extended. First, the process can be shortened, if the patient has already been the subject of a committee review. Second, the transfer period can be extended by court order.
(a) Prior Committee Review Can Shorten the Process
If, during a previous admission to a facility, a patient's attending physician and the review process have determined that LSMT is inappropriate, and the patient is readmitted to the same facility within six months, the hospital does not need to follow any of the above six steps.
This makes sense. Suppose the patient is transferred from the hospital to a long-term care facility. Then, the patient suffers an emergent issue such as respiratory distress and returns to the hospital. If the patient is in substantially the same condition, why start the entire dispute resolution process all over again? The result would probably be the same.
To bypass the dispute resolution process in such cases, the patient's attending physician and a consulting physician who is a member of the facility's review committee must confirm that the previous review committee decision is still applicable. They must document on the patient's readmission that the 'patient's condition either has not improved or has deteriorated since the review process was conducted.' 1 33
(b) Courts Can Sometimes Extend the Transfer Waiting Period
Just as TADA permits special circumstances to shorten the dispute resolution process, it also permits special circumstances to lengthen the process. While TADA gives the surrogate only ten days to find a facility willing to provide disputed LSMT, the surrogate may ask the 'appropriate district or county court' to extend this ten-day period.
But the surrogate's ability to obtain a judicial extension of the transfer period is extremely limited. TADA permits the court to grant such an extension only if there is a 'reasonable expectation that a physician or health care facility that will honor the patient's directive will be found if the time extension is granted.' Now that we have examined how TADA works, we can turn to look at how hospitals have used it. Unfortunately, TADA has never included any reporting requirements. 14 5 Consequently, there are no thorough and systematic data on how Texas hospitals have used TADA over the past fifteen years. Nevertheless, there are some small scale studies. Some were conducted right after TADA went into effect in 1999. Some were conducted in the 2000s. And a few more recent studies were conducted since 2010.
A Early Hospital Experience with TADA (1999 to 2004)
Baylor University Medical Center reported that in the 12 months before TADA, it had 14 futility cases. Of these, two patients died during the consultation and process even with maintenance of LSMT. In the other 12 cases, the family agreed to withdraw LSMT. But in one case it took the family about a month to agree. 146 In the first 16 months after TADA, Baylor reported 36 futility cases. In 29, the family promptly agreed to withdraw LSMT and focus on comfort care. Five cases were pursued through the TADA dispute resolution process. In three of these, the family agreed after receiving the review committee's report. In the other two cases, the patient died during the ten day waiting period. The families of 71 patients agreed to discontinue treatment. Thirty patients were transferred to another facility. And 78 patients died before the end of the 10-day waiting period. Eight patients improved and appropriateness of treatment was reassessed. After the 10 day period, 78 patients were still alive. Hospitals discontinued treatment for 33. And despite review committee decisions, hospitals continued treatment for 45.
A second study looked at five years' of information from eleven large hospitals and two years' worth of data from five other large hospitals. The surveyed hospitals reported a total of 974 medical futility cases. But they used TADA in only 65 of those cases. The hospitals actually withdrew 
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treatment in only 27 of those cases. Twenty-two patients died receiving treatment as they awaited transfers.
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C Recent Hospital Experience with TADA (2010 to 2015)
The most recent available data suggest that hospitals rarely use TADA. The Texas Hospital Association ('THA') surveyed its members in 2010, 2011, and 2012. THA reports that in 2009, the TADA dispute resolution process was initiated just two times at two multi-hospital systems. In 2010, the TADA process was initiated only one time at one hospital system. In 2011, usage ticked up. The THA survey shows that TADA was used 21 times by 16 hospitals or hospital systems.
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In 2012, the Texas Hospital Association again surveyed its member hospitals. The 202 respondents reported that TADA had been used 30 times between 2007 and 2012. Of those cases, ten patients died during the ten day period, six patients were transferred to another provider, and four continued treatment past the 10-day period. Extrapolating from this sample of one-third of Texas hospitals, one might estimate that TADA is used 15 times per year statewide. And one can estimate that treatment is actually withdrawn only five times per year.
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On the other hand, the THA data may not be accurate or representative. A single hospital study at Memorial Hermann examined its TADA experience from 2000 to 2013.152 The hospital reported that it had 34 cases during this time period (about 2.4 per year). The committee agreed with the referring physician in thirty of the 34 cases. Of these, the families of three agreed to discontinue treatment. Four were transferred. Seven died during the ten day waiting period. The hospital discontinued treatment for fifteen.
D Summary of Hospital Experience with TADA
While available studies suggest that Texas hospitals rarely use TADA, these understate the impact and effect of TADA. First, the more recent unpublished studies indicate far lower usage rates than the published studies. They may be neither statistically valid nor reliable. For example, it is unclear whether THA member hospitals are representative of all Texas hospitals. Second, focusing on only hospitals' actual use of TADA fails to account for its 'shadow effect.' 1 53 If families know the hospital has this 'weapon,' they may (reluctantly) consent to the recommended treatment plan, precluding the need to formally resort to the TADA mechanism. In this article, we look to constitutional requirements only as guideposts to assess TADA from an ethical and public policy perspective. The elements of due process have been well developed in hundreds of court opinions. And they provide a cogent framework for our fairness analysis.
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Before we begin assessing how well TADA satisfies specific elements of due process, we must first be mindful of two overarching principles. First, more extensive due process is required when a more significant interest is impacted. Perhaps the most significant fairness problem with TADA is its delegation of decision making power to the hospital's very own internal review committee. Since the committee is comprised of hospital clinicians and administrators, it is hardly a neutral and independent decision maker. 1 73 It is 'predisposed' to find for the hospital.
174
In one survey of 200 Texas hospitals, 56 per cent reported having a 'medical appropriateness review committee distinct from their ethics committee.' Half of these committees had five or fewer members. 1 75 Most were wholly comprised of physicians and hospital administrators. Hardly any included community representatives. There is a significant risk that such committees may be biased towards the interests of hospital management.
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Harvard Professor Robert Truog has lamented the TADA review committee's lack of neutrality in a long series of prominent articles. 'This is hardly an impartial tribunal.' 177 He has observed that review committee members 'are unavoidably "insiders".' 178 Truog is concerned that TADA 'gives an unwarranted amount of power to the clinicians and hospitals over patients and families who Other specific membership composition solutions include making at least one quarter of the committee non-hospital staff, or mandating the inclusion of members from disability and aging advocacy organisations. More radically, hospitals could use an entirely independent and external oversight committee otherwise unconnected to the hospital. 1 94 The key goal is to balance between embeddedness and detachment. 1 
B TADA Lacks Appellate Review
In addition to a neutral decision maker, the US Supreme Court has also held that procedural due process requires 'meaningful appellate review.' 19 6 Review is deemed 'meaningful' if it prevents the arbitrary deprivation of life or liberty. If a court or state agency could review the decision of the hospital review committee, such review could largely 'cure' the neutrality problem. 197 But TADA has a real accountability problem. It denies substantive judicial or agency review, making the hospital committee the forum of last resort.
19 8 A court may only grant a definite extension of time. And it may do even that only when there is a preponderance of evidence that a transfer will be accomplished. 1 The state legislature has also confirmed that the role for the courts is a narrow one. 'The court considers whether another provider who will honor the patient's directive is likely to be found; it does not address the issue of whether the decision to withdraw life support is valid.'
External oversight is essential. But that does not mean the appropriateness of LSMT should be determined by courts instead of hospital review committees. There is broad consensus that courts lack the requisite expertise and responsiveness necessary to engage in de novo review of these medical treatment decisions. In one case that challenged the validity of TADA under federal law, the court appointed a guardian ad litem for a patient, Stephen Jody Helman. Mr Helman submitted a fifty-page trial brief to the court observing that TADA 'is by no means perfect and could certainly be improved to make it fairer and less burdensome to patients and their representatives.' 22 0 Mr Helman pointed specifically to the 'short notice period.' Intractable Medical Futility Conflicts suggests that the average notice given to a surrogate prior to a review committee meeting was 7.9 days. 223 But nothing in TADA requires more than the 48-hour 'floor.' Some hospitals offer no more. Indeed, hospitals sometimes provide notice on a Friday afternoon for a Monday morning meeting.
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D TADA Fails to Assure a Meaningful Statement of Decision
While perhaps not in the same hierarchy as a neutral decision maker, appellate review and notice; another core element of procedural due process recognised by the US Supreme Court is a 'written statement' of decision. 225 This requirement serves several purposes. First, it helps assure that a factual basis supports the deprivation (or dispossession) of life, liberty, or property. 226 Second, it enables the affected individual to understand the grounds for the deprivation. 227 Third, it provides a record upon which to prepare for appeal. By enabling an appellate tribunal to review the review committee's reasons, a written statement that sets out all the relevant facts and evidence protects against arbitrary and capricious deprivations.
Unfortunately, TADA places no requirements on the extent of the explanation provided. While some hospitals provide detailed explanations, others do not. 228 In one case, the hospital used a preprinted single-page form titled 'Decision of the Committee for the Determination of Inappropriate/Futile Treatment.' The form includes no field for an explanation of why the review committee judged interventions to be inappropriate. And no reasons or explanations are provided.
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Hospital review committees 'like judges, will give more careful consideration to the problem if they are required to state not only the end result of their inquiry, but the process by which they reached it.' 2 30 Requiring a more complete written decision sharpens the decision makers' internal thought processes. 231 Moreover, written statements of decision show families that the committee seriously considered their arguments and facilitates judicial review.
What exactly review committees should include in their written statements of decision brings us to the next due process concern.
E TADA Fails to Provide Criteria to Guide Committee Review
Closely related to TADA's failure to assure a meaningful statement of decision is its failure to provide any criteria to guide the review committee. The Supreme Court has warned about vague statutes that fail to provide explicit standards for those who apply them. Such statutes increase the risk that the decision maker will resolve the case 'on an ad hoc and subjective basis with the attendant dangers of arbitrary and discriminatory application.' 232 This risk is especially high with TADA. Not only does TADA have no oversight, monitoring, or accountability but it also has no consistency or standardisation. 233 Without any guidepost anchors or criteria, there may be significant variability both in when and how hospitals invoke TADA. Enormous variability has already been well-documented across US intensive care units. 234 Moreover, this variability is expressly presumed by the transfer requirement.
The statute neither contains nor suggests any ascertainable standard for determining the propriety of continuing LSMT. 23 5 This creates three problems. First, it means that the decisions of review committees may not be as informed or reasoned as necessary. Second, the lack of guiding standards means that a single hospital review committee may disparately treat similarly situated patients. Third, it means that review committees at different hospitals may be deciding similar cases differently. Now, the reader may ask how TADA could include substantive criteria, when its very genesis lies in the inability of clinicians and philosophers to identify any such criteria. First, illegitimate bases for refusing treatment (such as the patient's race) could be specifically excluded. Second, while a universal definition of 'futility' has proven elusive, specific futile scenarios have garnered widespread support.
For example, many clinicians deem LSMT inappropriate: 1) when the burdens of treatment significantly outweigh the benefits, 2) when treatment can never achieve the patient's goals; 3) when death is imminent, 4) when the patient will never be able to survive outside of an ICU, and Intractable Medical Futility Conflicts 5) when the patient is permanently unconscious. 236 These principles cannot be automatically or mechanically applied in an algorithmic fashion. But neither must they be wholly disregarded. These and similar definitions, rules, and paradigm cases can productively inform and guide review committee deliberation and analysis.
F Other Due Process Concerns
While the above five elements of procedural due process are those that present the most serious problems with TADA, they are not the only ones. 237 The quality of TADA review committee decisions is also materially adversely affected by: 1) the review committee's lack of diverse membership, 2) the review committee's lack of training and competence, 3) the absence of standard meeting and hearing procedures, and 4) the absence of a requirement assuring the surrogate's participation.
First, TADA omits several key issues relating to the review committee. 238 In stark contrast to federal regulations governing Institutional Review Boards in the research context, TADA includes no details or guidelines concerning how a hospital composes its ethics committee. 2 39 TADA is silent as to: a) the overall number of committee members required, b) the inclusion of members from different professional disciplines c) the inclusion of lay or community members, and d) the inclusion of members with different gender, race, and disability status. 240 Second, TADA is silent as to the training or qualifications of the review committee members. 241 Many bioethics leaders have expressed "growing concern" about the practice of healthcare ethics consultation and how it is practiced. 2 4 2 The field is moving toward certification based on educational achievements and examination performance. Here, where the review committee acts as a decision maker, not as a mere advisor or consultant, the need to assure that it has the right knowledge and skills is even higher.
Third, TADA fails to define the 'rules by which an ethics committee must operate.'243 Committees have neither quorum requirements nor a system of review. 244 They do not report whether their decisions are unanimous or by a slim majority or whether dissent existed. 2 4 5 Some surrogates have even reported that they were stopped in the hall of the hospital, and later learned that brief and informal encounter constituted the review committee meeting. 246 Fourth, the 'right of confrontation and cross-examination is an essential and fundamental requirement' of due process. 24 7 But TADA assures only the surrogate's right to 'attend' the meeting. It does not assure the surrogate a right to ask questions of the attending physician. 248 Many hospitals voluntarily allow this. 24 9 But there is no provision in TADA that guarantees the right.
VII CONCLUSION
Striking the right balance between efficiency and fairness is difficult. These two goals are in tension. Dispute resolution procedures that better achieve one goal entail a tradeoff that correspondingly disrespects the other. On the one hand, the cost of less process is undermining deeply held principles of fundamental fairness. 250 On the other hand, the cost of more process is maintenance of the status quo, the continued administration of potentially non-beneficial treatment.
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TADA is a commendable attempt to 'steer a course between the Scylla of judicial review and the Charybdis of unfettered, unexamined physician discretion.' 25 2 But TADA places too much weight on efficiency at the cost of fairness.
The recalibration that I have defended in this article would not change the fundamental power of hospital review committees to authorise the withholding or withdrawal of inappropriate LSMT. Instead, the changes would be minor, affecting only 1) who is on the review committee, 2) how the committee conducts its meeting and makes its decision, and 3) the extent to which that decision can be reviewed. If TADA is used as infrequently as recent reports indicate, the costs of more process are circumscribed and determinate. This is a small price to pay to properly respect notions of due process, fundamental fairness, and fair procedure.
